- Datum20.11.2024
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalter
stock3
Thomas May
Moderator
Inventiva S.A. Actions Nom. (ADS)/1 o.N. Aktie
Verkaufen
Kaufen
Inventiva S.A. Actions Nom. (ADS)/1 o.N. Chart
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Inventiva S.A. Actions Nom. (ADS)/1 o.N. Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Stuttgart | VK | |||||
| Baader | VK | |||||
| gettex | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
0,37 %
Intraday
3,01 %
1 Woche
4,18 %
1 Monat
-39,33 %
Seit Jahresbeginn
-31,89 %
1 Jahr
-79,24 %
3 Jahre
Wikifolio
Passender Service zu Inventiva S.A. Actions Nom. (ADS)/1 o.N.
Webinar zu Inventiva S.A. Actions Nom. (ADS)/1 o.N.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)1,530-4,750
- Jahrestief / Hoch ($)1,530-4,750
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Inventiva S.A. Actions Nom. (ADS)/1 o.N.
Keine Dividenden verfügbar
Termine von Inventiva S.A. Actions Nom. (ADS)/1 o.N.
Termine werden geladen...
Beschreibung
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
